Defense Therapeutics Inc.: EXTRAORDINARY RESULTS: DEFENSE’S NEW ACCUTOXTM INTRANASAL REDUCED TUMOR NODULES BY 50% ON ANIMALS WITH LUNG CANCER

EQS-News: Defense Therapeutics Inc. / Keyword(s): Miscellaneous

Defense Therapeutics Inc.: EXTRAORDINARY RESULTS: DEFENSE’S NEW ACCUTOXTM INTRANASAL REDUCED TUMOR NODULES BY 50% ON ANIMALS WITH LUNG CANCER

20.12.2022 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

_________________________________________________________________

CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

RESULTS PERFORMED: THE NEW ACCUTOX OF THE DEFENSETM extension REDUCED BY 50% OF TUMOR NODULES IN ANIMALS WITH LUNG TUMORS

Vancouver, British Columbia, Canada, December 20th2022 – Defense Therapeutics Inc. (“Defence” or the “Agency”), a Canadian biopharmaceutical company specializing in the development of immuno-oncology vaccines and drug delivery technologies, has just completed a preclinical study using its intranasal formulation of AccuTOXTM extension in the context of animals with pre-established lung cancer. The study shows that AccuTOXTM extension administration as combination therapy with anti-PD1 immune checkpoint inhibitor dramatically reduced the level of pulmonary nodules compared to untreated or anti-PD1 treated control animals. This 50% reduction in tumor nodules in animals with pre-established lung tumors was achieved in a treatment plan of only 6 doses given over 2 weeks with AccuTOXTM extension anti-PD1 combination.

AccuTOX extensionTM extension as a pleiotropic anticancer treatment.

AccuTOX extensionTM extension The molecule was originally designed to exhibit improved anticancer properties over the original AccumTM extension molecule. Indeed the IC50 by AccuTOXTM extension is 30 times lower than that of AccumTM extension clearly demonstrating improved therapeutic potency as shown using a large set of mouse and human tumors. This is also exemplified by the increased therapeutic potency of the compound when directly injected into solid tumors in combination with various immune checkpoints (anti-PD-1, anti-CTLA4 and anti-CD47).

The sum of these results paved the way for testing the compound in another animal model of pre-established intranasally administered lung cancer. To this end, a series of maximum tolerated dose (MTD) studies were conducted to identify the volume, dosage, and tolerance of mice to repeated administration of AccuTOXTM extension. These studies show that AccuTOXTM extension it is well tolerated up to 3 mg/kg (5-6 times lower than the injectable dose) with a regimen of 6 administrations in 2 weeks. When tested using this program in animals with lung tumors, AccuTOXTM extension decreased the number of tumor nodules by more than 50%, especially in the group combined with the anti-PD1 immune checkpoint inhibitor.

“We are very satisfied with the versatile use of AccuTOXTM extension as cancer therapy. Not only has the compound shown great potential in the treatment of solid tumors, but we now have data showing that it can be further adapted and administered intranasally for the treatment of lungs with metastatic tumors, which is new hope for patients with lung cancer,” says Mr. Plouffe, CEO of Defense Therapeutics. “And this will open up a whole new horizon for AccuTOXTM extension as an anticancer treatment,” he adds. The global market size of Lung Cancer Therapies was estimated at USD 27.57 billion in 2021 and is projected to exceed approximately USD 55.6 billion by 2030 at the CAGR recorded by 8.11% from 2022 to 2030 according to precedence research.

https://www.precedenceresearch.com/lung-cancer-therapeutics-market

AccuTOX extensionTM extension is one of the Defense’s most advanced immuno-oncology programs. The company is currently preparing for the FDA meeting to obtain approval to initiate a Phase I study against solid tumors in 2023. Demonstrating excellent safety and tolerability profiles in patients, AccuTOXTM extension it can become the next generation cancer treatment for a wide range of indications.

Here is a link to a related video https://www.youtube.com/watch?v=Kgd2fUGP3BU

Defense information:

Defense Therapeutics is a publicly traded biotechnology company working on the design of next-generation vaccines and ADC products using its proprietary platform. The core of the Defense Therapeutics platform is ACCUMTM extension technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, greater efficacy and potency against catastrophic diseases such as cancer and infectious diseases can be achieved.

For more information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

[email protected]

www.defencetherapeutics.com

Cautionary Statement Regarding “Forward-Looking” Information.

This release includes certain statements that may be considered “forward-looking statements”. All statements contained in this release, other than statements of historical fact, that relate to events or developments that the Company anticipates will occur are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”. , “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “may” or “should” occur. While the Company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results could differ materially from those contained in the forward-looking statements. Factors that could cause actual results to differ materially from those of the forward-looking statements include regulatory actions, market prices and the continued availability of capital and financing, and general economic, market or trade conditions. Investors are cautioned that such statements are not guarantees of future performance and that actual results or developments could differ materially from those anticipated in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management as of the date they are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors change.

Neither CSE nor its market regulator, as that term is defined in CSE policies, accepts responsibility for the adequacy or accuracy of this release.

20.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

EQS distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.eqs-news.com

Add a Comment

Your email address will not be published. Required fields are marked *